期刊
NEUROLOGY
卷 75, 期 2, 页码 143-151出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181e7ca82
关键词
-
资金
- Robert H. Smith Family Foundation
- Elan Corporation
- Baxter International Inc.
- Forest Laboratories, Inc.
- NIH [R01AG023195, R01-AG11378, P50 AG16574, U01 AG 06786, R01 HL70825, NIA P01 AG 09215-20, NIA P30 AG 10124-18, NIA PO1 AG 17586-10, NIA 1PO1 AG19724- 07, NIA 1 U01 AG 024904-05, NINDS P50 NS053488-02, NIA UO1 AG029213-01, RC2NS069368, RC1AG035427, NIA P30AG036468]
- Takeda Pharmaceutical Company Ltd.
- Pfizer Inc
- Neuro-Hitech
- Abbott
- Martek
- Merck Co.
- Radiopharmaceuticals Inc.
- US Department of Defense [DAMD1701- 1-0764]
- Veterans Administration [MIRECC VISN 21]
- State of California
- NIH/NIA [AG11378, P50-AG16574, U01 AG024904-01]
- Mayo Foundation
- AstraZeneca AB
- Bayer Schering PharmaAG
- Bristol-Myers Squibb
- Eisai Global Clinical Development
- Genentech
- GE Healthcare
- GlaxoSmithKline
- Innogenetics
- Johnson Johnson
- Eli Lilly and Co.
- Novartis AG
- F. Hoffmann-LaRoche
- Schering-Plough
- Synarc Inc.
- Wyeth
- Alzheimer's Association
- Institute for the Study of Aging
Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], A beta(1-42)) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE epsilon 4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype. Neurology(R) 2010;75:143-151
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据